nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ORM1—Vandetanib—thyroid cancer	0.2	0.379	CbGbCtD
Tacrolimus—ALB—Vandetanib—thyroid cancer	0.0843	0.159	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0544	0.103	CbGbCtD
Tacrolimus—CYP3A7—Sorafenib—thyroid cancer	0.0544	0.103	CbGbCtD
Tacrolimus—CYP3A5—Sorafenib—thyroid cancer	0.0408	0.0772	CbGbCtD
Tacrolimus—ABCB1—Sorafenib—thyroid cancer	0.0266	0.0502	CbGbCtD
Tacrolimus—CYP3A4—Vandetanib—thyroid cancer	0.0264	0.0499	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—thyroid cancer	0.0161	0.0305	CbGbCtD
Tacrolimus—CYP3A4—Sorafenib—thyroid cancer	0.0159	0.0301	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—thyroid cancer	0.00966	0.0183	CbGbCtD
Tacrolimus—ABCA5—saliva-secreting gland—thyroid cancer	0.00615	0.111	CbGeAlD
Tacrolimus—ABCA5—trachea—thyroid cancer	0.00475	0.0854	CbGeAlD
Tacrolimus—PPP3CA—saliva-secreting gland—thyroid cancer	0.00416	0.0748	CbGeAlD
Tacrolimus—MTOR—neck—thyroid cancer	0.00394	0.0708	CbGeAlD
Tacrolimus—ABCA5—thyroid gland—thyroid cancer	0.00375	0.0675	CbGeAlD
Tacrolimus—FKBP1A—neck—thyroid cancer	0.00354	0.0637	CbGeAlD
Tacrolimus—ABCA5—head—thyroid cancer	0.00333	0.0599	CbGeAlD
Tacrolimus—PPP3CA—trachea—thyroid cancer	0.00321	0.0577	CbGeAlD
Tacrolimus—PPP3CA—thyroid gland—thyroid cancer	0.00254	0.0456	CbGeAlD
Tacrolimus—ABCA5—lymph node—thyroid cancer	0.00233	0.042	CbGeAlD
Tacrolimus—PPP3CA—head—thyroid cancer	0.00225	0.0405	CbGeAlD
Tacrolimus—FKBP1A—trachea—thyroid cancer	0.00213	0.0383	CbGeAlD
Tacrolimus—MTOR—thyroid gland—thyroid cancer	0.00187	0.0337	CbGeAlD
Tacrolimus—FKBP1A—thyroid gland—thyroid cancer	0.00168	0.0303	CbGeAlD
Tacrolimus—MTOR—head—thyroid cancer	0.00166	0.0299	CbGeAlD
Tacrolimus—PPP3CA—lymph node—thyroid cancer	0.00158	0.0283	CbGeAlD
Tacrolimus—FKBP1A—head—thyroid cancer	0.00149	0.0269	CbGeAlD
Tacrolimus—MTOR—lymph node—thyroid cancer	0.00116	0.0209	CbGeAlD
Tacrolimus—FKBP1A—lymph node—thyroid cancer	0.00105	0.0188	CbGeAlD
Tacrolimus—ORM1—lymph node—thyroid cancer	0.000819	0.0147	CbGeAlD
Tacrolimus—ALB—lymph node—thyroid cancer	0.000719	0.0129	CbGeAlD
Tacrolimus—ABCB1—trachea—thyroid cancer	0.000493	0.00886	CbGeAlD
Tacrolimus—ABCB1—thyroid gland—thyroid cancer	0.00039	0.00701	CbGeAlD
Tacrolimus—ABCB1—head—thyroid cancer	0.000346	0.00622	CbGeAlD
Tacrolimus—ABCB1—lymph node—thyroid cancer	0.000242	0.00436	CbGeAlD
Tacrolimus—Dry skin—Doxorubicin—thyroid cancer	0.000139	0.000467	CcSEcCtD
Tacrolimus—Pancreatitis—Epirubicin—thyroid cancer	0.000139	0.000467	CcSEcCtD
Tacrolimus—Vomiting—Sorafenib—thyroid cancer	0.000138	0.000466	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000138	0.000465	CcSEcCtD
Tacrolimus—Hypokalaemia—Doxorubicin—thyroid cancer	0.000138	0.000464	CcSEcCtD
Tacrolimus—Angina pectoris—Epirubicin—thyroid cancer	0.000138	0.000464	CcSEcCtD
Tacrolimus—Rash—Sorafenib—thyroid cancer	0.000137	0.000462	CcSEcCtD
Tacrolimus—Dermatitis—Sorafenib—thyroid cancer	0.000137	0.000461	CcSEcCtD
Tacrolimus—Breast disorder—Doxorubicin—thyroid cancer	0.000137	0.000461	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000136	0.000459	CcSEcCtD
Tacrolimus—Headache—Sorafenib—thyroid cancer	0.000136	0.000459	CcSEcCtD
Tacrolimus—Bronchitis—Epirubicin—thyroid cancer	0.000136	0.000458	CcSEcCtD
Tacrolimus—Pancytopenia—Epirubicin—thyroid cancer	0.000134	0.000452	CcSEcCtD
Tacrolimus—Gastritis—Doxorubicin—thyroid cancer	0.000134	0.000451	CcSEcCtD
Tacrolimus—Muscular weakness—Doxorubicin—thyroid cancer	0.000134	0.00045	CcSEcCtD
Tacrolimus—Dysuria—Epirubicin—thyroid cancer	0.000132	0.000445	CcSEcCtD
Tacrolimus—Neutropenia—Epirubicin—thyroid cancer	0.000132	0.000445	CcSEcCtD
Tacrolimus—Abdominal distension—Doxorubicin—thyroid cancer	0.000132	0.000443	CcSEcCtD
Tacrolimus—Asthma—Doxorubicin—thyroid cancer	0.000131	0.000441	CcSEcCtD
Tacrolimus—Dysphagia—Doxorubicin—thyroid cancer	0.000131	0.000441	CcSEcCtD
Tacrolimus—Influenza—Doxorubicin—thyroid cancer	0.000131	0.000441	CcSEcCtD
Tacrolimus—Pollakiuria—Epirubicin—thyroid cancer	0.000131	0.00044	CcSEcCtD
Tacrolimus—Nausea—Sorafenib—thyroid cancer	0.000129	0.000435	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000129	0.000435	CcSEcCtD
Tacrolimus—Weight increased—Epirubicin—thyroid cancer	0.000129	0.000433	CcSEcCtD
Tacrolimus—Pancreatitis—Doxorubicin—thyroid cancer	0.000128	0.000432	CcSEcCtD
Tacrolimus—Weight decreased—Epirubicin—thyroid cancer	0.000128	0.000431	CcSEcCtD
Tacrolimus—Hyperglycaemia—Epirubicin—thyroid cancer	0.000128	0.000429	CcSEcCtD
Tacrolimus—Angina pectoris—Doxorubicin—thyroid cancer	0.000128	0.000429	CcSEcCtD
Tacrolimus—Pneumonia—Epirubicin—thyroid cancer	0.000127	0.000427	CcSEcCtD
Tacrolimus—Infestation NOS—Epirubicin—thyroid cancer	0.000126	0.000424	CcSEcCtD
Tacrolimus—Infestation—Epirubicin—thyroid cancer	0.000126	0.000424	CcSEcCtD
Tacrolimus—Bronchitis—Doxorubicin—thyroid cancer	0.000126	0.000424	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000125	0.000421	CcSEcCtD
Tacrolimus—Pancytopenia—Doxorubicin—thyroid cancer	0.000124	0.000418	CcSEcCtD
Tacrolimus—Renal failure—Epirubicin—thyroid cancer	0.000124	0.000417	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000124	0.000416	CcSEcCtD
Tacrolimus—Jaundice—Epirubicin—thyroid cancer	0.000123	0.000414	CcSEcCtD
Tacrolimus—Stomatitis—Epirubicin—thyroid cancer	0.000123	0.000414	CcSEcCtD
Tacrolimus—Urinary tract infection—Epirubicin—thyroid cancer	0.000123	0.000413	CcSEcCtD
Tacrolimus—Conjunctivitis—Epirubicin—thyroid cancer	0.000123	0.000413	CcSEcCtD
Tacrolimus—Dysuria—Doxorubicin—thyroid cancer	0.000122	0.000412	CcSEcCtD
Tacrolimus—Neutropenia—Doxorubicin—thyroid cancer	0.000122	0.000412	CcSEcCtD
Tacrolimus—Sweating—Epirubicin—thyroid cancer	0.000121	0.000407	CcSEcCtD
Tacrolimus—Pollakiuria—Doxorubicin—thyroid cancer	0.000121	0.000407	CcSEcCtD
Tacrolimus—Haematuria—Epirubicin—thyroid cancer	0.00012	0.000405	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00012	0.000402	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000119	0.000401	CcSEcCtD
Tacrolimus—Weight increased—Doxorubicin—thyroid cancer	0.000119	0.000401	CcSEcCtD
Tacrolimus—Epistaxis—Epirubicin—thyroid cancer	0.000119	0.0004	CcSEcCtD
Tacrolimus—Weight decreased—Doxorubicin—thyroid cancer	0.000118	0.000399	CcSEcCtD
Tacrolimus—Sinusitis—Epirubicin—thyroid cancer	0.000118	0.000398	CcSEcCtD
Tacrolimus—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000118	0.000397	CcSEcCtD
Tacrolimus—Agranulocytosis—Epirubicin—thyroid cancer	0.000118	0.000396	CcSEcCtD
Tacrolimus—Pneumonia—Doxorubicin—thyroid cancer	0.000117	0.000395	CcSEcCtD
Tacrolimus—Infestation NOS—Doxorubicin—thyroid cancer	0.000117	0.000393	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—thyroid cancer	0.000117	0.000393	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000116	0.000389	CcSEcCtD
Tacrolimus—Bradycardia—Epirubicin—thyroid cancer	0.000115	0.000388	CcSEcCtD
Tacrolimus—Renal failure—Doxorubicin—thyroid cancer	0.000115	0.000386	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000114	0.000385	CcSEcCtD
Tacrolimus—Haemoglobin—Epirubicin—thyroid cancer	0.000114	0.000383	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—thyroid cancer	0.000114	0.000383	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—thyroid cancer	0.000114	0.000383	CcSEcCtD
Tacrolimus—Rhinitis—Epirubicin—thyroid cancer	0.000114	0.000382	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—thyroid cancer	0.000114	0.000382	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—thyroid cancer	0.000114	0.000382	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—thyroid cancer	0.000113	0.000381	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—thyroid cancer	0.000113	0.000381	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—thyroid cancer	0.000113	0.000379	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—thyroid cancer	0.000112	0.000378	CcSEcCtD
Tacrolimus—Sweating—Doxorubicin—thyroid cancer	0.000112	0.000377	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—thyroid cancer	0.000112	0.000376	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—thyroid cancer	0.000112	0.000375	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—thyroid cancer	0.000111	0.000374	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—thyroid cancer	0.000111	0.000374	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—thyroid cancer	0.000111	0.000374	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00011	0.000371	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—thyroid cancer	0.00011	0.00037	CcSEcCtD
Tacrolimus—Sinusitis—Doxorubicin—thyroid cancer	0.00011	0.000368	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—thyroid cancer	0.000109	0.000367	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—thyroid cancer	0.000109	0.000367	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—thyroid cancer	0.000107	0.00036	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—thyroid cancer	0.000107	0.000359	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—thyroid cancer	0.000106	0.000356	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—thyroid cancer	0.000106	0.000355	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—thyroid cancer	0.000105	0.000354	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—thyroid cancer	0.000105	0.000354	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—thyroid cancer	0.000105	0.000354	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—thyroid cancer	0.000105	0.000353	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—thyroid cancer	0.000105	0.000353	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—thyroid cancer	0.000105	0.000353	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000104	0.000351	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—thyroid cancer	0.000104	0.00035	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000104	0.000348	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—thyroid cancer	0.000103	0.000347	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000103	0.000346	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—thyroid cancer	0.000103	0.000346	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—thyroid cancer	0.000103	0.000346	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—thyroid cancer	0.000102	0.000344	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—thyroid cancer	0.000102	0.000343	CcSEcCtD
Tacrolimus—Chills—Epirubicin—thyroid cancer	0.000102	0.000342	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—thyroid cancer	0.000101	0.00034	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—thyroid cancer	0.000101	0.00034	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—thyroid cancer	0.0001	0.000337	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—thyroid cancer	9.93e-05	0.000334	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—thyroid cancer	9.91e-05	0.000333	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—thyroid cancer	9.86e-05	0.000332	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—thyroid cancer	9.86e-05	0.000332	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—thyroid cancer	9.8e-05	0.00033	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—thyroid cancer	9.77e-05	0.000329	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—thyroid cancer	9.73e-05	0.000327	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—thyroid cancer	9.73e-05	0.000327	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—thyroid cancer	9.72e-05	0.000327	CcSEcCtD
Tacrolimus—Tension—Epirubicin—thyroid cancer	9.68e-05	0.000326	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—thyroid cancer	9.66e-05	0.000325	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—thyroid cancer	9.58e-05	0.000322	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—thyroid cancer	9.54e-05	0.000321	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—thyroid cancer	9.51e-05	0.00032	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—thyroid cancer	9.48e-05	0.000319	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—thyroid cancer	9.47e-05	0.000318	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—thyroid cancer	9.45e-05	0.000318	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—thyroid cancer	9.41e-05	0.000316	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—thyroid cancer	9.36e-05	0.000315	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—thyroid cancer	9.29e-05	0.000313	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—thyroid cancer	9.26e-05	0.000312	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—thyroid cancer	9.18e-05	0.000309	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—thyroid cancer	9.15e-05	0.000308	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—thyroid cancer	9.13e-05	0.000307	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—thyroid cancer	9.13e-05	0.000307	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—thyroid cancer	9.12e-05	0.000307	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—thyroid cancer	9.06e-05	0.000305	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—thyroid cancer	8.99e-05	0.000302	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—thyroid cancer	8.95e-05	0.000301	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—thyroid cancer	8.94e-05	0.000301	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—thyroid cancer	8.89e-05	0.000299	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—thyroid cancer	8.86e-05	0.000298	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—thyroid cancer	8.86e-05	0.000298	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—thyroid cancer	8.84e-05	0.000297	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—thyroid cancer	8.83e-05	0.000297	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—thyroid cancer	8.83e-05	0.000297	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—thyroid cancer	8.77e-05	0.000295	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—thyroid cancer	8.72e-05	0.000293	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—thyroid cancer	8.67e-05	0.000292	CcSEcCtD
Tacrolimus—Cough—Epirubicin—thyroid cancer	8.61e-05	0.000289	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—thyroid cancer	8.6e-05	0.000289	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—thyroid cancer	8.54e-05	0.000287	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—thyroid cancer	8.51e-05	0.000286	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—thyroid cancer	8.47e-05	0.000285	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—thyroid cancer	8.43e-05	0.000284	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—thyroid cancer	8.4e-05	0.000282	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—thyroid cancer	8.4e-05	0.000282	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—thyroid cancer	8.4e-05	0.000282	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—thyroid cancer	8.39e-05	0.000282	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—thyroid cancer	8.37e-05	0.000281	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	8.34e-05	0.00028	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—thyroid cancer	8.3e-05	0.000279	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—thyroid cancer	8.23e-05	0.000277	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—thyroid cancer	8.21e-05	0.000276	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—thyroid cancer	8.2e-05	0.000276	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—thyroid cancer	8.18e-05	0.000275	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—thyroid cancer	8.17e-05	0.000275	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—thyroid cancer	8.12e-05	0.000273	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—thyroid cancer	8.06e-05	0.000271	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—thyroid cancer	8.05e-05	0.000271	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—thyroid cancer	8.05e-05	0.000271	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—thyroid cancer	8.02e-05	0.00027	CcSEcCtD
Tacrolimus—Infection—Epirubicin—thyroid cancer	8e-05	0.000269	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—thyroid cancer	7.96e-05	0.000268	CcSEcCtD
Tacrolimus—Shock—Epirubicin—thyroid cancer	7.92e-05	0.000266	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—thyroid cancer	7.91e-05	0.000266	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—thyroid cancer	7.89e-05	0.000265	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—thyroid cancer	7.88e-05	0.000265	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—thyroid cancer	7.88e-05	0.000265	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—thyroid cancer	7.86e-05	0.000264	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—thyroid cancer	7.82e-05	0.000263	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—thyroid cancer	7.78e-05	0.000262	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—thyroid cancer	7.77e-05	0.000261	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—thyroid cancer	7.77e-05	0.000261	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—thyroid cancer	7.77e-05	0.000261	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—thyroid cancer	7.74e-05	0.00026	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	7.72e-05	0.00026	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—thyroid cancer	7.68e-05	0.000258	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—thyroid cancer	7.67e-05	0.000258	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—thyroid cancer	7.6e-05	0.000256	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—thyroid cancer	7.52e-05	0.000253	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—thyroid cancer	7.51e-05	0.000253	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—thyroid cancer	7.45e-05	0.00025	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—thyroid cancer	7.45e-05	0.00025	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—thyroid cancer	7.4e-05	0.000249	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—thyroid cancer	7.33e-05	0.000247	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—thyroid cancer	7.33e-05	0.000246	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—thyroid cancer	7.3e-05	0.000246	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—thyroid cancer	7.29e-05	0.000245	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—thyroid cancer	7.28e-05	0.000245	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—thyroid cancer	7.27e-05	0.000244	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—thyroid cancer	7.23e-05	0.000243	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—thyroid cancer	7.23e-05	0.000243	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—PTCH1—thyroid cancer	7.2e-05	0.000611	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Doxorubicin—thyroid cancer	7.2e-05	0.000242	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—thyroid cancer	7.18e-05	0.000241	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—thyroid cancer	7.16e-05	0.000241	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	7.14e-05	0.000605	CbGpPWpGaD
Tacrolimus—Anorexia—Doxorubicin—thyroid cancer	7.1e-05	0.000239	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—thyroid cancer	7.09e-05	0.000238	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—NRAS—thyroid cancer	7.05e-05	0.000598	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CHST14—thyroid cancer	7.02e-05	0.000595	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	7.01e-05	0.000594	CbGpPWpGaD
Tacrolimus—Decreased appetite—Epirubicin—thyroid cancer	7e-05	0.000235	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—thyroid cancer	6.96e-05	0.000234	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—thyroid cancer	6.95e-05	0.000234	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—HRAS—thyroid cancer	6.95e-05	0.000589	CbGpPWpGaD
Tacrolimus—Fatigue—Epirubicin—thyroid cancer	6.94e-05	0.000233	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—NRG1—thyroid cancer	6.88e-05	0.000583	CbGpPWpGaD
Tacrolimus—Constipation—Epirubicin—thyroid cancer	6.88e-05	0.000232	CcSEcCtD
Tacrolimus—Pain—Epirubicin—thyroid cancer	6.88e-05	0.000232	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	6.88e-05	0.000583	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—HRAS—thyroid cancer	6.83e-05	0.000579	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KRAS—thyroid cancer	6.81e-05	0.000578	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KRAS—thyroid cancer	6.81e-05	0.000578	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	6.81e-05	0.000578	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TPR—thyroid cancer	6.81e-05	0.000577	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PRKAR1A—thyroid cancer	6.79e-05	0.000576	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	6.79e-05	0.000228	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—KRAS—thyroid cancer	6.75e-05	0.000572	CbGpPWpGaD
Tacrolimus—Insomnia—Doxorubicin—thyroid cancer	6.74e-05	0.000227	CcSEcCtD
Tacrolimus—MTOR—Disease—PRKAR1A—thyroid cancer	6.7e-05	0.000567	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—thyroid cancer	6.69e-05	0.000567	CbGpPWpGaD
Tacrolimus—Paraesthesia—Doxorubicin—thyroid cancer	6.69e-05	0.000225	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—KRAS—thyroid cancer	6.66e-05	0.000565	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—thyroid cancer	6.65e-05	0.000563	CbGpPWpGaD
Tacrolimus—Dyspnoea—Doxorubicin—thyroid cancer	6.64e-05	0.000223	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—thyroid cancer	6.63e-05	0.000223	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—MINPP1—thyroid cancer	6.63e-05	0.000562	CbGpPWpGaD
Tacrolimus—Somnolence—Doxorubicin—thyroid cancer	6.62e-05	0.000223	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—NRG1—thyroid cancer	6.61e-05	0.00056	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SST—thyroid cancer	6.59e-05	0.000559	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Epirubicin—thyroid cancer	6.58e-05	0.000221	CcSEcCtD
Tacrolimus—FKBP1A—Disease—NRG1—thyroid cancer	6.58e-05	0.000558	CbGpPWpGaD
Tacrolimus—Dyspepsia—Doxorubicin—thyroid cancer	6.56e-05	0.000221	CcSEcCtD
Tacrolimus—ALB—Folate Metabolism—TP53—thyroid cancer	6.55e-05	0.000555	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—HRAS—thyroid cancer	6.54e-05	0.000554	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TCF7L1—thyroid cancer	6.51e-05	0.000552	CbGpPWpGaD
Tacrolimus—Decreased appetite—Doxorubicin—thyroid cancer	6.47e-05	0.000218	CcSEcCtD
Tacrolimus—ALB—Metabolism—NDUFA13—thyroid cancer	6.43e-05	0.000545	CbGpPWpGaD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—thyroid cancer	6.43e-05	0.000216	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—thyroid cancer	6.42e-05	0.000216	CcSEcCtD
Tacrolimus—MTOR—Disease—MEN1—thyroid cancer	6.4e-05	0.000542	CbGpPWpGaD
Tacrolimus—Urticaria—Epirubicin—thyroid cancer	6.39e-05	0.000215	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—thyroid cancer	6.37e-05	0.000214	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—thyroid cancer	6.37e-05	0.000214	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—thyroid cancer	6.36e-05	0.000214	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—thyroid cancer	6.36e-05	0.000214	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CALCA—thyroid cancer	6.34e-05	0.000538	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—KRAS—thyroid cancer	6.31e-05	0.000534	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—HRAS—thyroid cancer	6.28e-05	0.000532	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—HRAS—thyroid cancer	6.25e-05	0.00053	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	6.22e-05	0.000527	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—HRAS—thyroid cancer	6.22e-05	0.000527	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—HRAS—thyroid cancer	6.19e-05	0.000524	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—HRAS—thyroid cancer	6.16e-05	0.000522	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Doxorubicin—thyroid cancer	6.14e-05	0.000206	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—AKT1—thyroid cancer	6.13e-05	0.00052	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.09e-05	0.000205	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—KRAS—thyroid cancer	6.07e-05	0.000515	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	6.07e-05	0.000514	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CHST14—thyroid cancer	6.05e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—PTEN—thyroid cancer	6.04e-05	0.000512	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—BRAF—thyroid cancer	6.04e-05	0.000512	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	6.03e-05	0.000511	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—AKT1—thyroid cancer	6.03e-05	0.000511	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	5.98e-05	0.000507	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	5.98e-05	0.000507	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRG1—thyroid cancer	5.94e-05	0.000504	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Epirubicin—thyroid cancer	5.93e-05	0.000199	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—thyroid cancer	5.92e-05	0.000199	CcSEcCtD
Tacrolimus—FKBP1A—Disease—TERT—thyroid cancer	5.91e-05	0.000501	CbGpPWpGaD
Tacrolimus—Abdominal pain—Doxorubicin—thyroid cancer	5.89e-05	0.000198	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—thyroid cancer	5.89e-05	0.000198	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.88e-05	0.000499	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	5.87e-05	0.000497	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	5.81e-05	0.000492	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HRAS—thyroid cancer	5.79e-05	0.000491	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—HRAS—thyroid cancer	5.79e-05	0.000491	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	5.79e-05	0.000491	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—AKT1—thyroid cancer	5.78e-05	0.00049	CbGpPWpGaD
Tacrolimus—Asthenia—Epirubicin—thyroid cancer	5.77e-05	0.000194	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CDK1—thyroid cancer	5.74e-05	0.000487	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—HRAS—thyroid cancer	5.74e-05	0.000486	CbGpPWpGaD
Tacrolimus—Pruritus—Epirubicin—thyroid cancer	5.69e-05	0.000192	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	5.69e-05	0.000482	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—HRAS—thyroid cancer	5.66e-05	0.00048	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HPGD—thyroid cancer	5.66e-05	0.00048	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HIF1A—thyroid cancer	5.65e-05	0.000479	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NDUFA13—thyroid cancer	5.64e-05	0.000478	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.56e-05	0.000471	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—AKT1—thyroid cancer	5.54e-05	0.00047	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—AKT1—thyroid cancer	5.52e-05	0.000468	CbGpPWpGaD
Tacrolimus—Diarrhoea—Epirubicin—thyroid cancer	5.51e-05	0.000185	CcSEcCtD
Tacrolimus—MTOR—Signaling by FGFR—AKT1—thyroid cancer	5.49e-05	0.000465	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	5.49e-05	0.000465	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Doxorubicin—thyroid cancer	5.49e-05	0.000185	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—AKT1—thyroid cancer	5.46e-05	0.000463	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—AKT1—thyroid cancer	5.44e-05	0.000461	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NRAS—thyroid cancer	5.39e-05	0.000457	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—thyroid cancer	5.36e-05	0.000454	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	5.36e-05	0.000454	CbGpPWpGaD
Tacrolimus—Asthenia—Doxorubicin—thyroid cancer	5.34e-05	0.00018	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—TERT—thyroid cancer	5.34e-05	0.000452	CbGpPWpGaD
Tacrolimus—Dizziness—Epirubicin—thyroid cancer	5.32e-05	0.000179	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—CHST14—thyroid cancer	5.3e-05	0.000449	CbGpPWpGaD
Tacrolimus—Pruritus—Doxorubicin—thyroid cancer	5.27e-05	0.000177	CcSEcCtD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	5.24e-05	0.000444	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	5.24e-05	0.000444	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—thyroid cancer	5.16e-05	0.000437	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.15e-05	0.000437	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	5.13e-05	0.000435	CbGpPWpGaD
Tacrolimus—Vomiting—Epirubicin—thyroid cancer	5.12e-05	0.000172	CcSEcCtD
Tacrolimus—MTOR—Signaling by FGFR in disease—AKT1—thyroid cancer	5.11e-05	0.000433	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—AKT1—thyroid cancer	5.11e-05	0.000433	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	5.11e-05	0.000433	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HIF1A—thyroid cancer	5.1e-05	0.000433	CbGpPWpGaD
Tacrolimus—Diarrhoea—Doxorubicin—thyroid cancer	5.1e-05	0.000171	CcSEcCtD
Tacrolimus—MTOR—Disease—CALCA—thyroid cancer	5.09e-05	0.000432	CbGpPWpGaD
Tacrolimus—Rash—Epirubicin—thyroid cancer	5.07e-05	0.000171	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—thyroid cancer	5.07e-05	0.000171	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—AKT1—thyroid cancer	5.07e-05	0.00043	CbGpPWpGaD
Tacrolimus—Headache—Epirubicin—thyroid cancer	5.04e-05	0.00017	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	5.02e-05	0.000426	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—AKT1—thyroid cancer	5e-05	0.000424	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDK1—thyroid cancer	4.99e-05	0.000423	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—thyroid cancer	4.92e-05	0.000166	CcSEcCtD
Tacrolimus—ALB—Metabolism—HPGD—thyroid cancer	4.88e-05	0.000413	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—thyroid cancer	4.88e-05	0.000413	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	4.85e-05	0.000411	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNA2—thyroid cancer	4.8e-05	0.000407	CbGpPWpGaD
Tacrolimus—Nausea—Epirubicin—thyroid cancer	4.78e-05	0.000161	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—TSHR—thyroid cancer	4.77e-05	0.000404	CbGpPWpGaD
Tacrolimus—Vomiting—Doxorubicin—thyroid cancer	4.74e-05	0.000159	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—AKT1—thyroid cancer	4.73e-05	0.000401	CbGpPWpGaD
Tacrolimus—Rash—Doxorubicin—thyroid cancer	4.7e-05	0.000158	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—thyroid cancer	4.69e-05	0.000158	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—PRKAR1A—thyroid cancer	4.69e-05	0.000397	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—BRAF—thyroid cancer	4.68e-05	0.000397	CbGpPWpGaD
Tacrolimus—Headache—Doxorubicin—thyroid cancer	4.67e-05	0.000157	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—KRAS—thyroid cancer	4.64e-05	0.000393	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDK1—thyroid cancer	4.61e-05	0.000391	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRG1—thyroid cancer	4.61e-05	0.000391	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PTEN—thyroid cancer	4.6e-05	0.00039	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—AKT1—thyroid cancer	4.56e-05	0.000386	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	4.53e-05	0.000384	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IFNA2—thyroid cancer	4.5e-05	0.000381	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TPR—thyroid cancer	4.5e-05	0.000381	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—thyroid cancer	4.5e-05	0.000381	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MEN1—thyroid cancer	4.48e-05	0.00038	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.48e-05	0.000379	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	4.43e-05	0.000375	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—thyroid cancer	4.42e-05	0.000149	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—TP53—thyroid cancer	4.4e-05	0.000373	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HPGD—thyroid cancer	4.27e-05	0.000362	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTEN—thyroid cancer	4.25e-05	0.00036	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—BRAF—thyroid cancer	4.23e-05	0.000358	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TERT—thyroid cancer	4.14e-05	0.000351	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	4.12e-05	0.000349	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NRAS—thyroid cancer	4.11e-05	0.000348	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.08e-05	0.000346	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTCH1—thyroid cancer	4.05e-05	0.000343	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRG1—thyroid cancer	4.01e-05	0.00034	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HIF1A—thyroid cancer	3.96e-05	0.000335	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.95e-05	0.000335	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—thyroid cancer	3.95e-05	0.000334	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.92e-05	0.000332	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—thyroid cancer	3.87e-05	0.000328	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NRAS—thyroid cancer	3.79e-05	0.000321	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—thyroid cancer	3.78e-05	0.00032	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.76e-05	0.000319	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.72e-05	0.000316	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SST—thyroid cancer	3.71e-05	0.000314	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRG1—thyroid cancer	3.7e-05	0.000314	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.59e-05	0.000305	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CALCA—thyroid cancer	3.57e-05	0.000302	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—thyroid cancer	3.54e-05	0.0003	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—AKT1—thyroid cancer	3.48e-05	0.000295	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.47e-05	0.000294	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PTEN—thyroid cancer	3.45e-05	0.000292	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SLC5A5—thyroid cancer	3.37e-05	0.000285	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TERT—thyroid cancer	3.32e-05	0.000282	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PTEN—thyroid cancer	3.31e-05	0.000281	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTEN—thyroid cancer	3.3e-05	0.000279	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.29e-05	0.000279	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—thyroid cancer	3.29e-05	0.000279	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—BRAF—thyroid cancer	3.28e-05	0.000278	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CHST14—thyroid cancer	3.27e-05	0.000277	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—thyroid cancer	3.26e-05	0.000277	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TPR—thyroid cancer	3.25e-05	0.000276	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDK1—thyroid cancer	3.23e-05	0.000274	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	3.2e-05	0.000271	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HIF1A—thyroid cancer	3.18e-05	0.000269	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—thyroid cancer	3.08e-05	0.000261	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—thyroid cancer	3.08e-05	0.000261	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—thyroid cancer	3.01e-05	0.000255	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTEN—thyroid cancer	2.98e-05	0.000252	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—thyroid cancer	2.95e-05	0.00025	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—thyroid cancer	2.94e-05	0.000249	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—thyroid cancer	2.9e-05	0.000246	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—RXRA—thyroid cancer	2.83e-05	0.00024	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TPR—thyroid cancer	2.8e-05	0.000237	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—thyroid cancer	2.77e-05	0.000235	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.76e-05	0.000234	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PRKAR1A—thyroid cancer	2.75e-05	0.000233	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—thyroid cancer	2.66e-05	0.000225	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—thyroid cancer	2.65e-05	0.000225	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—thyroid cancer	2.65e-05	0.000224	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BRAF—thyroid cancer	2.63e-05	0.000223	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HPGD—thyroid cancer	2.63e-05	0.000223	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRG1—thyroid cancer	2.59e-05	0.00022	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—thyroid cancer	2.54e-05	0.000215	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—thyroid cancer	2.53e-05	0.000215	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.5e-05	0.000212	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TPR—thyroid cancer	2.45e-05	0.000208	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.45e-05	0.000208	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—thyroid cancer	2.45e-05	0.000208	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC5A5—thyroid cancer	2.43e-05	0.000206	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.41e-05	0.000205	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—thyroid cancer	2.39e-05	0.000203	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—thyroid cancer	2.33e-05	0.000197	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—thyroid cancer	2.31e-05	0.000196	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—thyroid cancer	2.29e-05	0.000194	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—thyroid cancer	2.25e-05	0.000191	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HIF1A—thyroid cancer	2.23e-05	0.000189	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—thyroid cancer	2.16e-05	0.000183	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—thyroid cancer	2.15e-05	0.000182	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—thyroid cancer	2.13e-05	0.00018	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.1e-05	0.000178	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC5A5—thyroid cancer	2.1e-05	0.000178	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.07e-05	0.000176	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—thyroid cancer	2.06e-05	0.000175	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—RXRA—thyroid cancer	2.05e-05	0.000173	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—thyroid cancer	2.03e-05	0.000172	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—thyroid cancer	2.01e-05	0.00017	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—thyroid cancer	1.99e-05	0.000168	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.96e-05	0.000166	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—thyroid cancer	1.94e-05	0.000165	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—thyroid cancer	1.91e-05	0.000162	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—thyroid cancer	1.9e-05	0.000161	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—thyroid cancer	1.85e-05	0.000157	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—thyroid cancer	1.84e-05	0.000156	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.84e-05	0.000156	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—thyroid cancer	1.79e-05	0.000152	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—thyroid cancer	1.79e-05	0.000151	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—thyroid cancer	1.77e-05	0.00015	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—RXRA—thyroid cancer	1.76e-05	0.000149	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—thyroid cancer	1.72e-05	0.000145	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.71e-05	0.000145	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—thyroid cancer	1.68e-05	0.000142	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—thyroid cancer	1.65e-05	0.00014	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—thyroid cancer	1.58e-05	0.000134	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—RXRA—thyroid cancer	1.54e-05	0.000131	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—thyroid cancer	1.54e-05	0.000131	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TPR—thyroid cancer	1.51e-05	0.000128	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—thyroid cancer	1.51e-05	0.000128	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.49e-05	0.000126	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—thyroid cancer	1.44e-05	0.000122	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—thyroid cancer	1.42e-05	0.000121	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.41e-05	0.000119	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—thyroid cancer	1.35e-05	0.000114	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—thyroid cancer	1.33e-05	0.000113	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—thyroid cancer	1.31e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—thyroid cancer	1.3e-05	0.00011	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—thyroid cancer	1.29e-05	0.000109	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—thyroid cancer	1.28e-05	0.000109	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—thyroid cancer	1.23e-05	0.000104	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—thyroid cancer	1.23e-05	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—thyroid cancer	1.21e-05	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—thyroid cancer	1.16e-05	9.82e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—thyroid cancer	1.16e-05	9.81e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.13e-05	9.59e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—thyroid cancer	1.11e-05	9.43e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—thyroid cancer	1.08e-05	9.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—thyroid cancer	1.07e-05	9.06e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.02e-05	8.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—thyroid cancer	9.97e-06	8.45e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—thyroid cancer	9.74e-06	8.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—RXRA—thyroid cancer	9.51e-06	8.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—thyroid cancer	8.86e-06	7.51e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—thyroid cancer	8.86e-06	7.51e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—thyroid cancer	8.75e-06	7.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—thyroid cancer	8.47e-06	7.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—thyroid cancer	7.66e-06	6.5e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—thyroid cancer	7.63e-06	6.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—thyroid cancer	7.48e-06	6.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—thyroid cancer	7.06e-06	5.99e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—thyroid cancer	6.68e-06	5.67e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—thyroid cancer	6e-06	5.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—thyroid cancer	5.11e-06	4.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.72e-06	4e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—thyroid cancer	4.4e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—thyroid cancer	4.12e-06	3.49e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—thyroid cancer	3.85e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—thyroid cancer	2.37e-06	2.01e-05	CbGpPWpGaD
